NLGN3 and glioma: We measured the expression of NLGN3 in serum EVs from glioma patients (n =18) and healthy individuals (n =9) and found that the mRNA level of NLGN3 was significantly higher in glioma patients than in healthy donors (**P < 0.01), although the mRNA level of NLGN3 varied between each glioma patient (Figure 5A).